Important

These guidelines are for healthcare professionals who are trained in their use. JPAC cannot answer individual donor queries or provide personal medical advice. Help with such matters may be available through a local Blood Transfusion and Tissue Transplantation Service.

Donations must not be accepted from donors who exhibit health risks that are not listed in these guidelines without referral to, and acceptance by, a Designated Clinical Support Officer.

The Whole Blood and Components Donor Selection Guidelines (WB-DSG) form a constituent part of Chapter 3 of the Guidelines for the Blood Transfusion and Tissue Transplantation Services in the UK (Red Book).

JPAC is responsible for these guidelines and receives professional advice from its specialist Standing Advisory Committees and other relevant expert groups. Guidelines are reviewed regularly to ensure that donations are of the highest quality and of sufficient quantity to meet the needs of recipients.

Comments about the content of the WB-DSG, including notification of errors, omissions and suggestions for improvements, should be sent to the interim Chair of the Standing Advisory Committee on Care and Selection of Donors (SACCSD):

Dr Jayne Hughes c/o JPACOffice@nhsbt.nhs.uk

General principles

These guidelines apply to donors giving whole blood or blood components (red cells, platelets, plasma and granulocytes) for therapeutic use. Donors are selected firstly to ensure that they do not come to harm from giving their donation and secondly to ensure that their donation is unlikely to harm any recipient.

The ultimate responsibility for the selection of donors rests with the Medical Director of each Blood Transfusion and Tissue Transplantation Service in the UK.

The immediate responsibility is with the Qualified Healthcare Professional in clinical charge of an individual donor session. When it is not clear from these guidelines if an individual donor is suitable, no donation should be taken until it has been discussed and agreed with a Designated Clinical Support Officer.

Only persons in good health should be accepted as donors. The prospective donor must be evaluated for their fitness to donate on the day by a suitably qualified person who has undergone appropriate training to use these guidelines to select or defer a donor. They must verify their assessment by signing the donation record.

Special note must be taken of the content of the Blood safety entry.

It is the responsibility of session staff to ensure that donors clearly understand the nature of the donation process and the associated risks involved, as explained in the available literature. The donors must also understand the health check and other medical information presented to them. Donors are asked about confidential aspects of their medical history, hence great care must be taken over privacy and confidentiality.

Where there is separate guidance for Whole Blood and for Component donors, this is made clear. When there is a recognised risk to either the donor or the recipient, the guidelines must be followed.

Autologous transfusion

These guidelines do not apply to donors wishing to give their blood for autologous transfusions. Specific guidelines should be referred to.

Non-therapeutic donations

Donors whose serum, plasma or cells will be used for laboratory, rather than therapeutic, purposes are generally subject to the same medical selection criteria. However, some decisions regarding their suitability to donate may be varied by a Designated Clinical Support Officer.

Therapeutic venesection

Patients referred for therapeutic venesection must not be accepted at donor sessions. The exception is donors with haemochromatosis. They may be accepted after referral to, and consideration by, a Designated Clinical Support Officer.

Use of the A-Z index

Any medical condition or possible contraindication to donation, elicited at any point during the donation process, must be managed as indicated by its respective guideline entry. A complete list of available entries can be found in the A-Z index of the WB-DSG. Any collected material which, as a result, is unsuitable for clinical use must be clearly labelled as unfit for use.

If there is more than one contraindication to donation, any that indicate the need to permanently defer the donor must be applied. This will mean that the donor is withdrawn from the donor panel. If withdrawal is not required, then the longest applicable deferral period must be applied.

Donors who undergo component donation procedures may be subject to additional or separate criteria compared to whole blood donors. Reference should be made to Chapter 3 of the Red Book.

Any new health risks identified during the donor selection process should be notified to the Standing Advisory Committee on Care and Selection of Donors, so that they can be considered for incorporation into future revisions of the WB-DSG.

Guideline terminology

The following terms may be used for each section of a guideline entry:

Also known as

Alternative names for the entry.

Definition(s)

Clarification of key terms and concepts within the entry.

Includes

Any conditions, treatments or other factors covered by the entry.

Excludes

Any conditions, treatments or other factors not covered by the entry.

Obligatory

Reasons why a donor must not donate.

Discretionary

Reasons why a donor may be permitted to donate.

These statements are conditional and all criteria that must be fulfilled will come before the final statement that they may be accepted.

If the donor fulfils these requirements, as well as all others that apply, then they can be accepted.

See if relevant

Other entries which may need to be consulted, depending upon the information provided by the donor.

Additional information

Further detail as to why any particular action is required.

The following terms may be used within the text of the entry:

Must not donate

The donor must not donate if any of the statements apply to them, unless a discretion clearly applies.

If the deferral depends on time-related factors, the donor must be clearly advised when they will become eligible to donate again.

If the deferral is not time limited (i.e. it is likely to be permanent) the donor must be clearly advised why they cannot donate.

See

The specified entry must be consulted.

Refer to a Designated Clinical Support Officer

When there is a need to seek further advice, the Designated Clinical Support Officer is a suitably trained person authorised to undertake this task by the Medical Director or their nominated deputy.

The following information is provided at the end of each entry:

Reason for change

Provides information about the most recent changes to the entry.

Version details

Provides the Edition and Release number of the current version of the entry and the date of publication.

Medication

The underlying illness suffered by a donor, rather than the properties of any drug they are taking, is the usual reason for an ineligiblity to donate.

In general, traces of drugs in donations are harmless to their recipients. However, donors treated with certain drugs are deferred for periods associated with the pharmacokinetic properties of the drug. Examples are drugs used to treat acne, psoriasis, and some prostate problems. All such drugs have their own entry.

Drugs that can affect platelet function are listed in the drug index together with the deferral period required before a donor's blood can be used for platelet production.

Inspection of the donor

All donors should appear to be in good health and the skin at the venepuncture site should be free from disease.

Intoxication, either by alcohol or drugs, should be a reason for not accepting a donor (see Addiction and drug abuse).

A qualified clinical professional must assess disabled donors (see Disabled donor).

Document and Change Control

The WB-DSG is under the continuing review of the Standing Advisory Committees on Care and Selection of Donors (SACCSD) and on Transfusion Transmitted Infection (SACTTI) to ensure that they are accurate and up to date.

All changes are the responsibility of the Professional Director of JPAC and have the approval of the Executive Working Group (EWG) and the JPAC Board.

The following document control terminology is used:

Change Notification

This notifies the Medical Director and the Quality Manager of each of the four UK Services to upcoming changes to the guidelines.

The implementation of any changes is the responsibility of the individual Services.

Edition

An extensive revision of the guidelines.

Release

Changes to the current Edition of the guidelines which involve a change to the medical or scientific content.

Issue

Changes to the current Release of the guidelines which do not involve a change to the medical or scientific content or have been made to correct an error or omission.

Each Release of the guidelines will be Issue 01 unless otherwise stated.

Changes to the live versions of the guidelines (this website)

The website will always display the most recent version of each entry.

Any errors should be notified to JPACOffice@nhsbt.nhs.uk.

Changes to the offline versions of the guidelines (Source Files)

The Quality Manager of each Blood Service will be notified of upcoming changes by Change Notification and will effect changes to local offline versions of the guidelines. Source Files for upcoming releases will be posted on this website prior to publication of any changes.

The Quality Manager is responsible for ensuring that there is an effective Version Control and Change Procedure in operation within their Service to ensure that only up-to-date versions are in use and that all authorised copies, electronic and paper, are traceable.

Individual users of the offline versions of the guidelines are responsible for ensuring that they are using the most recently published version.

Information:

This page was last updated in WB-DSG Edition 203 Release XX (Date)